gastroparesis

Novo Nordisk’s blockbuster diabetes drug, repurposed as a weight-loss trend, is now at the center of one of the largest pharmaceutical litigations in recent years. The legal fallout over Ozempic (semaglutide) continues to escalate, with more than 1,800 lawsuits consolidated into federal multidistrict litigation (MDL No. 3094) in the Eastern District of Pennsylvania. Analysts now…